Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerHeikki Joensuu, Jorma Isola, Taina Turpeenniemi‐Hujanen et al.|New England Journal of Medicine|2006Cited by 1.4k
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirusAnna Kanerva, Akseli Hemminki, Kurt R. Zinn et al.|Molecular Therapy|2003Cited by 172
An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene ExpressionAkseli Hemminki, Ronald D. Alvarez, Н. В. Белоусова et al.|Molecular Therapy|2001Cited by 127
[A serine/threonine kinase gene defective in Peutz-Jeghers syndrome].Akseli Hemminki, La Chapelle A de, Egle Avizienyte et al.|PubMed|1998Cited by 113
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor ControlDafne C.A. Quixabeira, Akseli Hemminki|Frontiers in Immunology|2021Cited by 36